Reactive oxygen species, SUMOylation, and endothelial inflammation

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Le, Nhat Tu ^a   Corsetti, James P ^a   Dehoff Sparks, Janet L ^a   Sparks, Charles E ^a   Fujiwara, Keigi ^a   Abe, Jun Ichi ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P22 PHOX SUBUNIT; STAT1 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VITAMIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL INFLAMMATION; ENDOTHELIUM CELL; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR SIZE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; RECURRENCE RISK; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUMOYLATION; TRANSCRIPTION REGULATION; UBIQUITINATION; VASCULAR DISEASE;

EID: 84876511553     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/678190     Document Type: Review

References (142)

1. Gill G., SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes and Development 2004 18 17 2046 2059 2-s2.0-4444301185 10.1101/gad.1214604 (Pubitemid 39166622)
2. Seeler J. S., Dejean A., Nuclear and unclear functions of sumo. Nature Reviews Molecular Cell Biology 2003 4 9 690 699 2-s2.0-0041837510 10.1038/nrm1200 (Pubitemid 37082184)
3. Melchior F., Schergaut M., Pichler A., SUMO: ligases, isopeptidases and nuclear pores. Trends in Biochemical Sciences 2003 28 11 612 618 2-s2.0-1542501958 10.1016/j.tibs.2003.09.002 (Pubitemid 38352808)
4. Melchior F., SUMOnonclassical ubiquitin. Annual Review of Cell and Developmental Biology 2000 16 591 626 2-s2.0-0034523266 10.1146/annurev.cellbio. 16.1.591 (Pubitemid 32037518)
5. Su H. L., Li S. S. L., Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002 296 1-2 65 73 2-s2.0-0037151769 10.1016/S0378-1119(02)00843-0 (Pubitemid 35287325)
6. Woo C. H., Abe J. I., SUMO-a post-translational modification with therapeutic potential? Current Opinion in Pharmacology 2010 10 2 146 155 2-s2.0-77949725836 10.1016/j.coph.2009.12.001
7. Desterro J. M. P., Thomson J., Hay R. T., Ubch9 conjugates SUMO but not ubiquitin. FEBS Letters 1997 417 3 297 300 2-s2.0-0030728212 10.1016/S0014-5793(97)01305-7 (Pubitemid 27511608)
8. Gong L., Kamitani T., Fujise K., Caskey L. S., Yeh E. T. H., Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. Journal of Biological Chemistry 1997 272 45 28198 28201 2-s2.0-0030657575 10.1074/jbc.272.45.28198 (Pubitemid 27517756)
9. Hay R. T., Vuillard L., Desterro J. M. P., Rodriguez M. S., Control of NF- κ B transcriptional activation by signal induced proteolysis of I κ B α Philosophical Transactions of the Royal Society B 1999 354 1389 1601 1609 2-s2.0-0033615293 (Pubitemid 29464091)
10. Liu B., Shuai K., Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends in Pharmacological Sciences 2008 29 10 505 509 2-s2.0-52949117651 10.1016/j.tips.2008.07.008
11. Chung C. D., Liao J., Liu B., Rao X., Jay P., Berta P., Shuai K., Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997 278 5344 1803 1805 2-s2.0-0030725378 10.1126/science.278.5344.1803 (Pubitemid 27527648)
12. Liu B., Liao J., Rao X., Kushner S. A., Chung C. D., Chang D. D., Shuai K. E., Inhibition of Stat1-mediated gene activation by PIAS1. Proceedings of the National Academy of Sciences of the United States of America 1998 95 18 10626 10631 2-s2.0-0032169599 10.1073/pnas.95.18.10626 (Pubitemid 28413118)
13. Rytinki M. M., Kaikkonen S., Pehkonen P., Jääskeläinen T., Palvimo J. J., PIAS proteins: pleiotropic interactors associated with SUMO. Cellular and Molecular Life Sciences 2009 66 18 3029 3041 2-s2.0-73649111322
14. Ghosh S., Karin M., Missing pieces in the NF- κ B puzzle. Cell 2002 109 2 S81 S96 2-s2.0-0036234459 10.1016/S0092-8674(02)00703-1 (Pubitemid 34457854)
15. Darnell J. E., STATs and gene regulation. Science 1997 277 5332 1630 1635 2-s2.0-0030840464 10.1126/science.277.5332.1630 (Pubitemid 27446219)
16. Tahk S., Liu B., Chernishof V., Wong K. A., Wu H., Shuai K., Control of specificity and magnitude of NF- κ B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proceedings of the National Academy of Sciences of the United States of America 2007 104 28 11643 11648 2-s2.0-34547423214 10.1073/pnas.0701877104 (Pubitemid 47175066)
17. Palvimo J. J., PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochemical Society Transactions 2007 35 6 1405 1408 2-s2.0-37749037140 10.1042/BST0351405
18. Hochstrasser M., SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 2001 107 1 5 8 2-s2.0-0035812848 10.1016/S0092-8674(01)00519-0 (Pubitemid 32972031)
19. Takahashi Y., Kikuchi Y., Yeast PIAS-type Ull1/Siz1 is composed of SUMO ligase and regulatory domains. Journal of Biological Chemistry 2005 280 43 35822 35828 2-s2.0-27744503961 10.1074/jbc.M506794200 (Pubitemid 41633849)
20. Reindle A., Belichenko I., Bylebyl G. R., Chen X. L., Gandhi N., Johnson E. S., Multiple domains in Siz SUMO ligases contribute to substrate selectivity. Journal of Cell Science 2006 119 22 4749 4757 2-s2.0-33845708819 10.1242/jcs.03243 (Pubitemid 44964271)
21. McKellar G. E., McCarey D. W., Sattar N., McInnes I. B., Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews 2009 6 6 410 417 2-s2.0-69249222895 10.1038/nrcardio.2009.57
22. Liu B., Yang R., Wong K. A., Getman C., Stein N., Teitell M. A., Cheng G., Wu H., Shuai K., Negative regulation of NF- κ B signaling by PIAS1. Molecular and Cellular Biology 2005 25 3 1113 1123 2-s2.0-12844275070 10.1128/MCB.25.3.1113-1123.2005 (Pubitemid 40165817)
23. Liu B., Mink S., Wong K. A., Stein N., Getman C., Dempsey P. W., Wu H., Shuai K., PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nature Immunology 2004 5 9 891 898 2-s2.0-4644367257 10.1038/ni1104 (Pubitemid 39276233)
24. Liu B., Yang Y., Chernishof V., Loo R. R. O., Jang H., Tahk S., Yang R., Mink S., Shultz D., Bellone C. J., Loo J. A., Shuai K., Proinflammatory stimuli induce IKK α -mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007 129 5 903 914 2-s2.0-34249039031 10.1016/j.cell.2007.03. 056 (Pubitemid 46802704)
25. Huang T. T., Wuerzberger-Davis S. M., Wu Z. H., Miyamoto S., Sequential modification of NEMO/IKK γ by SUMO-1 and ubiquitin mediates NF- κ B activation by genotoxic stress. Cell 2003 115 5 565 576 2-s2.0-0344305376 10.1016/S0092-8674(03)00895-X (Pubitemid 37506045)
26. Mabb A. M., Wuerzberger-Davis S. M., Miyamoto S., PIASy mediates NEMO sumoylation and NF- κ B activation in response to genotoxic stress. Nature Cell Biology 2006 8 9 986 993 2-s2.0-33748188499 10.1038/ncb1458 (Pubitemid 44314730)
27. Ohshima T., Koga H., Shimotahno K., Transcriptional activity of peroxisome proliferator-activated receptor γ is modulated by SUMO-1 modification. Journal of Biological Chemistry 2004 279 28 29551 29557 2-s2.0-3142716146 10.1074/jbc.M403866200 (Pubitemid 38915836)
28. Lim S., Ahn B. Y., Chung S. S., Park H. S., Cho B. J., Kim M., Choi S. H., Lee I. K., Lee S. W., Choi S. J., Chung C. H., Cho Y. M., Lee H. K., Park K. S., Effect of a peroxisome proliferator-activated receptor γ sumoylation mutant on neointimal formation after balloon injury in rats. Atherosclerosis 2009 206 2 411 417 2-s2.0-70349414652 10.1016/j.atherosclerosis.2009.02.031
29. Gutkind J. S., Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Science's STKE 2000 2000 40 RE1 2-s2.0-0034636685
30. Roberts O. L., Holmes K., Müller J., Cross D. A. E., Cross M. J., ERK5 and the regulation of endothelial cell function. Biochemical Society Transactions 2009 37 6 1254 1259 2-s2.0-70450182094 10.1042/BST0371254
31. Kasler H. G., Victoria J., Duramad O., Winoto A., ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Molecular and Cellular Biology 2000 20 22 8382 8389 2-s2.0-0033761543 10.1128/MCB.20.22.8382-8389.2000
32. Yan C., Luo H., Lee J. D., Abe J. I., Berk B. C., Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. Journal of Biological Chemistry 2001 276 14 10870 10878 2-s2.0-0035815665 10.1074/jbc.M009286200 (Pubitemid 38089264)
33. Zhou G., Zhao Qin Bao, Dixon J. E., Components of a new human protein kinase signal transduction pathway. Journal of Biological Chemistry 1995 270 21 12665 12669 2-s2.0-0029055761
34. Lee J. D., Ulevitch R. J., Han J., Primary structure of BMK1: a new mammalian MAP kinase. Biochemical and Biophysical Research Communications 1995 213 2 715 724 2-s2.0-0029162078 10.1006/bbrc.1995.2189
35. Akaike M., Che W., Marmarosh N. L., Ohta S., Osawa M., Ding B., Berk B. C., Yan C., Abe J. I., The hinge-helix 1 region of peroxisome proliferator-activated receptor γ 1 (PPAR γ 1) mediates interaction with extracellular signal-regulated kinase 5 and PPAR γ 1 transcriptional activation: involvement in flow-induced PPAR γ activation in endothelial cells. Molecular and Cellular Biology 2004 24 19 8691 8704 2-s2.0-4544318079 10.1128/MCB.24.19.8691-8704.2004 (Pubitemid 39245088)
36. Gimbrone M. A., Topper J. N., Nagel T., Anderson K. R., Garcia-Cardeña G., Endothelial dysfunction, hemodynamic forces, and atherogenesis. Annals of the New York Academy of Sciences 2000 902 230 240 2-s2.0-0034085698 (Pubitemid 30389128)
37. Davies P. F., Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nature Clinical Practice Cardiovascular Medicine 2009 6 1 16 26 2-s2.0-58049213790 10.1038/ncpcardio1397
38. Dekker R. J., Van Soest S., Fontijn R. D., Salamanca S., De Groot P. G., VanBavel E., Pannekoek H., Horrevoets A. J. G., Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood 2002 100 5 1689 1698 2-s2.0-0036721376 10.1182/blood-2002-01-0046 (Pubitemid 34925146)
39. SenBanerjee S., Lin Z., Atkins G. B., Greif D. M., Rao R. M., Kumar A., Feinberg M. W., Chen Z., Simon D. I., Luscinskas F. W., Michel T. M., Gimbrone M. A., García-Cardeña G., Jain M. K., KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. Journal of Experimental Medicine 2004 199 10 1305 1315 2-s2.0-2542500709 10.1084/jem.20031132 (Pubitemid 38685723)
40. Suzuki T., Aizawa K., Matsumura T., Nagai R., Vascular implications of the Krüppel-like family of transcription factors. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1135 1141 2-s2.0-20144368777 10.1161/01.ATV.0000165656.65359.23 (Pubitemid 40776599)
41. Parmar K. M., Larman H. B., Dai G., Zhang Y., Wang E. T., Moorthy S. N., Kratz J. R., Lin Z., Jain M. K., Gimbrone M. A., García-Cardeña G., Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. Journal of Clinical Investigation 2006 116 1 49 58 2-s2.0-31044453008 10.1172/JCI24787 (Pubitemid 43121790)
42. Lin Z., Kumar A., SenBanerjee S., Staniszewski K., Parmar K., Vaughan D. E., Gimbrone M. A., Balasubramanian V., García-Cardeña G., Jain M. K., Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circulation Research 2005 96 5 e48 57 2-s2.0-20744451022
43. Heo K. S., Lee H., Nigro P., Thomas T., Le N. T., Chang E., McClain C., Reinhart-King C. A., King M. R., Berk B. C., Fujiwara K., Woo C. H., Abe J. I., PKC ζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. Journal of Cell Biology 2011 193 5 867 884 2-s2.0-79959442340 10.1083/jcb.201010051
44. Ni C. W., Qiu H., Rezvan A., Kwon K., Nam D., Son D. J., Visvader J. E., Jo H., Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood 2010 116 15 e66 e73 2-s2.0-77957935751 10.1182/blood-2010-04-278192
45. Woo C. H., Shishido T., McClain C., Lim J. H., Li J. D., Yang J., Yan C., Abe J. I., Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circulation Research 2008 102 5 538 545 2-s2.0-40949145324 10.1161/CIRCRESAHA.107.156877 (Pubitemid 351416753)
46. Shishido T., Woo C. H., Ding B., McClain C., Molina C. A., Yan C., Yang J., Abe J. I., Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: implications for diabetic ventricular dysfunction after myocardial infarction. Circulation Research 2008 102 11 1416 1425 2-s2.0-44949114361 10.1161/CIRCRESAHA.107.168138
47. Görlach A., Brandes R. P., Nguyen K., Amidi M., Dehghani F., Busse R., A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circulation Research 2000 87 1 26 32 2-s2.0-0034617071 (Pubitemid 30456931)
48. Magid R., Davies P. F., Endothelial protein kinase C isoform identity and differential activity of PKC ζ in an athero-susceptible region of porcine aorta. Circulation Research 2005 97 5 443 449 2-s2.0-24744449131 10.1161/01.RES.0000179767.37838.60 (Pubitemid 41298174)
49. Garin G., Abe J. I., Mohan A., Lu W., Yan C., Newby A. C., Rhaman A., Berk B. C., Flow antagonizes TNF- α signaling in endothelial cells by inhibiting caspase-dependent PKC ζ processing. Circulation Research 2007 101 1 97 105 2-s2.0-34447648183 10.1161/CIRCRESAHA.107.148270 (Pubitemid 47094628)
50. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U. M., p53 has a direct apoptogenic role at the mitochondria. Molecular Cell 2003 11 3 577 590 2-s2.0-0037349289 10.1016/S1097-2765(03)00050-9 (Pubitemid 36385115)
51. Mercer J., Figg N., Stoneman V., Braganza D., Bennett M. R., Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circulation Research 2005 96 6 667 674 2-s2.0-16444370187 10.1161/01.RES.0000161069.15577.ca (Pubitemid 40478334)
52. Bischof O., Schwamborn K., Martin N., Werner A., Sustmann C., Grosschedl R., Dejean A., The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Molecular Cell 2006 22 6 783 794 2-s2.0-33745210316 10.1016/j.molcel.2006.05.016
53. Garner E., Martinon F., Tschopp J., Beard P., Raj K., Cells with defective p53-p21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6. Cancer Research 2007 67 16 7631 7637 2-s2.0-34548036682 10.1158/0008-5472.CAN-07-0334 (Pubitemid 47281355)
54. Murray-Zmijewski F., Slee E. A., Lu X., A complex barcode underlies the heterogeneous response of p53 to stress. Nature Reviews Molecular Cell Biology 2008 9 9 702 712 2-s2.0-50149097809 10.1038/nrm2451
55. Van Vlijmen B. J. M., Gerritsen G., Franken A. L., Boesten L. S. M., Kockx M. M., Gijbels M. J., Vierboom M. P., Van Eck M., Van de Water B., Van Berkel T. J. C., Havekes L. M., Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE3-Leiden transgenic mice. Circulation Research 2001 88 8 780 786 2-s2.0-0035957575 (Pubitemid 32429973)
56. Tian H., Wittmack E. K., Jorgensen T. J., p21(WAF1/CIP1) Antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Research 2000 60 3 679 684 2-s2.0-0033621560 (Pubitemid 30094567)
57. Garner E., Raj K., Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 2008 7 3 277 282 2-s2.0-40549111934 (Pubitemid 351366487)
58. Ryan K. M., Ernst M. K., Rice N. R., Vousden K. H., Role of NF- κ B in p53-mediated programmed cell death. Nature 2000 404 6780 892 897 2-s2.0-0034689773 10.1038/35009130 (Pubitemid 30230343)
59. Zheng S. J., Lamhamedi-Cherradi S. E., Wang P., Xu L., Chen Y. H., Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 2005 54 5 1423 1428 2-s2.0-17844392396 10.2337/diabetes.54.5.1423 (Pubitemid 40586673)
60. Kumar A., Kim C.-S., Hoffman T. A., Naqvi A., Dericco J., Jung S.-B., Lin Z., Jain M. K., Irani K., P53 Impairs endothelial function by transcriptionally repressing kruppel-Like factor 2. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 1 133 141 2-s2.0-78650868271 10.1161/ATVBAHA.110.215061
61. Ben-Levy R., Leighton I. A., Doza Y. N., Attwood P., Morrice N., Marshall C. J., Cohen P., Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO Journal 1995 14 23 5920 5930 2-s2.0-0028806565
62. Engel K., Kotlyarov A., Gaestel M., Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO Journal 1998 17 12 3363 3371 2-s2.0-0032526988 10.1093/emboj/17.12.3363 (Pubitemid 28279510)
63. Engel K., Schultz H., Martin F., Kotlyarov A., Plath K., Hahn M., Heinemann U., Gaestel M., Constitutive activation of mitogen-activated protein kinase-activated protein kinase 2 by mutation of phosphorylation sites and an A-helix motif. Journal of Biological Chemistry 1995 270 45 27213 27221 2-s2.0-0028875318 10.1074/jbc.270.45.27213
64. Chrestensen C. A., Schroeder M. J., Shabanowitz J., Hunt D. F., Pelo J. W., Worthington M. T., Sturgill T. W., MAPKAP Kinase 2 Phosphorylates Tristetraprolin on in Vivo Sites Including Ser178, a Site Required for 14-3-3 Binding. Journal of Biological Chemistry 2004 279 11 10176 10184 2-s2.0-1642332899 10.1074/jbc.M310486200 (Pubitemid 38372622)
65. Manke I. A., Nguyen A., Lim D., Stewart M. Q., Elia A. E. H., Yaffe M. B., MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G 2/M transition and S phase progression in response to UV irradiation. Molecular Cell 2005 17 1 37 48 2-s2.0-11344286593 10.1016/j.molcel.2004.11.021 (Pubitemid 40075363)
66. Stoecklin G., Stubbs T., Kedersha N., Wax S., Rigby W. F. C., Blackwell T. K., Anderson P., MK2-induced tristetraprolin:14-3-3 Complexes prevent stress granule association and ARE-mRNA decay. EMBO Journal 2004 23 6 1313 1324 2-s2.0-1942471656 10.1038/sj.emboj.7600163 (Pubitemid 38525003)
67. Stokoe D., Engel K., Campbell D. G., Cohen P., Gaestel M., Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Letters 1992 313 3 307 313 2-s2.0-0026457201 10.1016/0014-5793(92)81216-9
68. Wang X., Khaleque M. A., Mei J. Z., Zhong R., Gaestel M., Calderwood S. K., Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits transcriptional activity and promotes HSP90 binding. Journal of Biological Chemistry 2006 281 2 782 791 2-s2.0-33644872354 10.1074/jbc. M505822200
69. Kotlyarov A., Yannoni Y., Fritz S., Laa K., Telliez J. B., Pitman D., Lin L. L., Gaestel M., Distinct cellular functions of MK2. Molecular and Cellular Biology 2002 22 13 4827 4835 2-s2.0-0036273201 10.1128/MCB.22.13.4827-4835.2002 (Pubitemid 34620417)
70. Ben-Levy R., Hooper S., Wilson R., Paterson H. F., Marshall C. J., Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Current Biology 1998 8 19 1049 1057 2-s2.0-0032563807 (Pubitemid 28451029)
71. Wójciak-Stothard B., Entwistle A., Garg R., Ridley A. J., Regulation of TNF- α -induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. Journal of Cellular Physiology 1998 176 1 150 165 2-s2.0-2642615752 10.1002/(SICI)1097- 4652(199807)176:1150::AID-JCP17>3.0.CO;2-B (Pubitemid 28277205)
72. Kiemer A. K., Weber N. C., Fürst R., Bildner N., Kulhanek-Heinze S., Vollmar A. M., Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF- α -induced actin polymerization and endothelial permeability. Circulation Research 2002 90 8 874 881 2-s2.0-0037013159 10.1161/01.RES.0000017068.58856.F3 (Pubitemid 34633879)
73. Chang E., Heo K. S., Woo C. H., Lee H., Le N. T., Thomas T. N., Fujiwara K., Abe J. I., MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood 2011 117 8 2527 2537 2-s2.0-79952181259 10.1182/blood-2010-08-302281
74. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H. D., Gaestel M., MAPKAP kinase 2 is essential for LPS-induced TNF- α biosynthesis. Nature Cell Biology 1999 1 2 94 97 2-s2.0-0033145354 (Pubitemid 129501950)
75. Neininger A., Kontoyiannis D., Kotlyarov A., Winzen R., Eckert R., Volk H. D., Holtmann H., Kollias G., Gaestel M., MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. Journal of Biological Chemistry 2002 277 5 3065 3068 2-s2.0-0036479125 10.1074/jbc.C100685200 (Pubitemid 34953164)
76. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A. D., Radzioch D., Clark A. R., Blackshear P. J., Kotlyarov A., Gaestel M., Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Molecular and Cellular Biology 2006 26 6 2399 2407 2-s2.0-33644753147 10.1128/MCB.26.6.2399-2407.2006 (Pubitemid 43346938)
77. Culbert A. A., Skaper S. D., Howlett D. R., Evans N. A., Facci L., Soden P. E., Seymour Z. M., Guillot F., Gaestel M., Richardson J. C., MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity: relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry 2006 281 33 23658 23667 2-s2.0-33747632142 10.1074/jbc.M513646200 (Pubitemid 44274141)
78. Jagavelu K., Tietge U. J. F., Gaestel M., Drexler H., Schieffer B., Bavendiek U., Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circulation Research 2007 101 11 1104 1112 2-s2.0-36348954401 10.1161/CIRCRESAHA.107.156075 (Pubitemid 350146436)
79. Rueckschloss U., Galle J., Holtz J., Zerkowski H. R., Morawietz H., Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001 104 15 1767 1772 2-s2.0-0035834028 (Pubitemid 32963340)
80. Takemoto M., Liao J. K., Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 11 1712 1719 2-s2.0-0035572718 (Pubitemid 34219772)
81. Biasucci L. M., Biasillo G., Stefanelli A., Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical Chemistry and Laboratory Medicine 2010 48 12 1685 1691 2-s2.0-78951485501 10.1515/CCLM.2010.277
82. Wassmann S., Laufs U., Müller K., Konkol C., Ahlbory K., Bäurmer A. T., Linz W., Böhm M., Nickenig G., Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 2 300 305 2-s2.0-0036162113 10.1161/hq0202.104081 (Pubitemid 34127043)
83. Schönbeck U., Libby P., Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004 109 21 II18 II26 2-s2.0-2642536741 (Pubitemid 38724152)
84. Jain M. K., Ridker P. M., Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews Drug Discovery 2005 4 12 977 987 2-s2.0-31844451010 10.1038/nrd1901
85. Ortego M., Bustos C., Hernández-Presa M. A., Tuñón J., Díaz C., Hernández G., Egido J., Atorvastatin reduces NF- κ B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999 147 2 253 261 2-s2.0-0032757209 10.1016/S0021-9150(99)00193-8 (Pubitemid 29512257)
86. Planavila A., Laguna J. C., Vázquez-Carrera M., Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor- κ B activation. Biochimica et Biophysica Acta 2005 1687 1-3 76 83 2-s2.0-13644255995 10.1016/j.bbalip.2004.11. 004 (Pubitemid 40228987)
87. Ennezat P. V., Vannesson C., Bouabdallaoui N., Maréchaux S., Asseman P., Lejemtel T. H., Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction. Expert Opinion on Pharmacotherapy 2011 12 6 883 897 2-s2.0-79952773487 10.1517/14656566.2011.543675
88. Tom B., Dendorfer A., De Vries R., Saxena P. R., Danser A. H. J., Bradykinin potentiation by ACE inhibitors: a matter of metabolism. British Journal of Pharmacology 2002 137 2 276 284 2-s2.0-0036739363 10.1038/sj.bjp.0704862
89. Miguel-Carrasco J. L., Zambrano S., Blanca A. J., Mate A., Vázquez C. M., Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. Journal of Inflammation 2010 7, article 21 2-s2.0-77953025722 10.1186/1476-9255-7-21
90. Basta G., Schmidt A. M., De Caterina R., Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular Research 2004 63 4 582 592 2-s2.0-4043058031 10.1016/j.cardiores.2004.05.001 (Pubitemid 39078671)
91. Kamioka M., Ishibashi T., Sugimoto K., Uekita H., Nagai R., Sakamoto N., Ando K., Ohkawara H., Teramoto T., Maruyama Y., Takeishi Y., Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. Journal of Atherosclerosis and Thrombosis 2010 17 6 590 600 2-s2.0-77954691788
92. Anderson D., Phillips B. J., Comparative in vitro and in vivo effects of antioxidants. Food and Chemical Toxicology 1999 37 9-10 1015 1025 2-s2.0-0032861815 10.1016/S0278-6915(99)00089-7 (Pubitemid 29481806)
93. Traber M. G., Stevens J. F., Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radical Biology and Medicine 2011 51 5 1000 1013 2-s2.0-79958252054 10.1016/j.freeradbiomed.2011.05.017
94. Stephens N. G., Parsons A., Schofield P. M., Kelly F., Cheeseman K., Mitchinson M. J., Brown M. J., Randomised controlled trial of vitamin E in patients with coronary disease: cambridge Heart Antioxidant Study (CHAOS). The Lancet 1996 347 9004 781 786 2-s2.0-0029925181 10.1016/S0140-6736(96)90866-1 (Pubitemid 26091640)
95. Harrison D. G., Gongora M. C., Guzik T. J., Widder J., Oxidative stress and hypertension. Journal of the American Society of Hypertension 2007 1 1 30 44 2-s2.0-34247877763 10.1016/j.jash.2006.11.006 (Pubitemid 46696606)
96. Schramm A., Matusik P., Osmenda G., Guzik T. J., Targeting NADPH oxidases in vascular pharmacology. Vascular Pharmacology 2012 56 216 231 2-s2.0-84858964091 10.1016/j.vph.2012.02.012
97. Gamkrelidze M., Mamamtavrishvili N., Bejitashvili N., Sanikidze T., Ratiani L., Role of oxidative stress in pathogenesis of atherosclerosis. Georgian Medical News 2008 163 54 57 2-s2.0-64849102255
98. Madamanchi N. R., Vendrov A., Runge M. S., Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 1 29 38 2-s2.0-11144225245 10.1161/01.ATV.0000150649.39934.13 (Pubitemid 40054251)
99. Soccio M., Toniato E., Evangelista V., Carluccio M., De Caterina R., Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. European Journal of Clinical Investigation 2005 35 5 305 314 2-s2.0-18744396081 10.1111/j.1365-2362.2005.01500.x (Pubitemid 40675604)
100. Inoue N., Kawashima S., Kanazawa K., Yamada S., Akita H., Yokoyama M., Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998 97 2 135 137 2-s2.0-0031940241 (Pubitemid 28124668)
101. 242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. Atherosclerosis 2008 196 1 461 468 2-s2.0-38049087505 10.1016/j.atherosclerosis.2006.12.007
102. 242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000 102 15 1744 1747 2-s2.0-0034633838
103. 242T polymorphism and lipoprotein oxidation. Clinica Chimica Acta 2003 335 1-2 101 107 2-s2.0-0242317400 10.1016/S0009-8981(03)00284-5 (Pubitemid 37338314)
104. Florentin M., Liberopoulos E. N., Wierzbicki A. S., Mikhailidis D. P., Multiple actions of high-density lipoprotein. Current Opinion in Cardiology 2008 23 4 370 378 2-s2.0-44649096384 10.1097/HCO.0b013e3283043806 (Pubitemid 351787103)
105. deGoma E. M., deGoma R. L., Rader D. J., Beyond high-density lipoprotein cholesterol levels. Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. Journal of the American College of Cardiology 2008 51 23 2199 2211 2-s2.0-44449103671 10.1016/j.jacc.2008.03.016 (Pubitemid 351754991)
106. Sviridov D., Mukhamedova N., Remaley A. T., Chin-Dusting J., Nestel P., Antiatherogenic functionality of high density lipoprotein: how much versus how good. Journal of Atherosclerosis and Thrombosis 2008 15 2 52 62 2-s2.0-47249113367
107. Ragbir S., Farmer J. A., Dysfunctional high-density lipoprotein and atherosclerosis. Current Atherosclerosis Reports 2010 12 5 343 348 2-s2.0-77956265233 10.1007/s11883-010-0091-x
108. Shao B., Oda M. N., Oram J. F., Heinecke J. W., Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chemical Research in Toxicology 2010 23 3 447 454 2-s2.0-77949362124 10.1021/tx9003775
109. Ansell B. J., Fonarow G. C., Fogelman A. M., The paradox of dysfunctional high-density lipoprotein. Current Opinion in Lipidology 2007 18 4 427 434 2-s2.0-34447341178 10.1097/MOL.0b013e3282364a17 (Pubitemid 47051922)
110. Kontush A., Chapman M. J., Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews 2006 58 3 342 374 2-s2.0-33748681287 10.1124/pr.58.3.1 (Pubitemid 44394906)
111. Onat A., Hergenç G., Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011 60 4 499 512 2-s2.0-79952984934 10.1016/j.metabol.2010.04.018
112. Von Eckardstein A., Schulte H., Assmann G., Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 1999 99 14 1925 2-s2.0-0033551078 (Pubitemid 29181429)
113. De Backer G., De Bacquer D., Kornitzer M., Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis 1998 137 supplement S1 S6 2-s2.0-0031802046 10.1016/S0021-9150(97)00310-9 (Pubitemid 28294200)
114. Jeppesen J., Hein H. O., Suadicani P., Gyntelberg F., Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998 97 11 1029 1036 2-s2.0-0032562257
115. Bittner V., Simon J. A., Fong J., Blumenthal R. S., Newby K., Stefanick M. L., Correlates of high hdl cholesterol among women with coronary heart disease. American Heart Journal 2000 139 2 I 288 296 2-s2.0-0033951012 (Pubitemid 30090806)
116. Shimoni N., Kaplan M., Keidar S., Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: association with increased plasma oxidative state. Israel Medical Association Journal 2003 5 10 702 705 2-s2.0-0242721124 (Pubitemid 37369033)
117. Agerholm-Larsen B., Nordestgaard B. G., Steffensen R., Jensen G., Tybjærg-Hansen A., Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000 101 16 1907 1912 2-s2.0-0034712706 (Pubitemid 30225270)
118. Gnasso A., Motti C., Irace C., Di Gennaro I., Pujia A., Leto E., Ciamei M., Crivaro A., Bernardini S., Federici G., Cortese C., The Arg allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Atherosclerosis 2002 164 2 289 295 2-s2.0-0036801786 10.1016/S0021-9150(02)00070-9 (Pubitemid 35223079)
119. DeLemos A. S., Wolfe M. L., Long C. J., Sivapackianathan R., Rader D. J., Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 2002 106 11 1321 1326 2-s2.0-0037056085 10.1161/01.CIR.0000028423.07623.6A (Pubitemid 35013033)
120. Ma K., Cilingiroglu M., Otvos J. D., Ballantyne C. M., Marian A. J., Chan L., Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure and metabolism. Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2748 2753 2-s2.0-0344406740 10.1073/pnas.0438039100 (Pubitemid 36297570)
121. Broedl U. C., Jin W., Rader D. J., Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends in Cardiovascular Medicine 2004 14 5 202 206 2-s2.0-3242689803 10.1016/j.tcm.2004.03.003 (Pubitemid 38942829)
122. Grundy S. M., Vega G. L., Otvos J. D., Rainwater D. L., Cohen J. C., Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. Journal of Lipid Research 1999 40 2 229 234 2-s2.0-0032958840 (Pubitemid 29069796)
123. Ruel I. L., Couture P., Cohn J. S., Bensadoun A., Marcil M., Lamarche B., Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. Journal of Lipid Research 2004 45 8 1528 1537 2-s2.0-3442882762 10.1194/jlr.M400090-JLR200 (Pubitemid 39006981)
124. Corsetti J. P., Ryan D., Rainwater D. L., Moss A. J., Zareba W., Sparks
125. Corsetti J. P., Gansevoort R. T., Navis G., Sparks C. E., Dullaart R. P. F., LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis 2011 214 2 373 376 2-s2.0-79151480742 10.1016/j.atherosclerosis.2010.11.029
126. Corsetti J. P., Gansevoort R. T., Bakker S. J. L., Navis G., Sparks C. E., Dullaart R. P. F., Apolipoprotein e predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein. Metabolism 2012 61 7 996 1002 2-s2.0-84862135204 10.1016/j.metabol.2011.11.010
127. Corsetti J. P., Ryan D., Moss A. J., Mccarthy J. J., Goldenberg I., Zareba W., Sparks C. E., Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thrombosis and Haemostasis 2011 106 6 1170 1178 2-s2.0-82555193688 10.1160/TH11-03-0206
128. Corsetti J. P., Zareba W., Moss A. J., Sparks C. E., Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 2005 183 2 293 300 2-s2.0-27644505610 10.1016/j.atherosclerosis.2005.03.046 (Pubitemid 41579280)
129. Corsetti J. P., Zareba W., Moss A. J., Rainwater D. L., Sparks C. E., Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006 187 1 191 197 2-s2.0-33744514658 10.1016/j. atherosclerosis.2005.09.012 (Pubitemid 43817014)
130. Corsetti J. P., Ryan D., Moss A. J., Rainwater D. L., Zareba W., Sparks C. E., Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 3 548 554 2-s2.0-40749130457 10.1161/ATVBAHA.107.155556
131. Corsetti J. P., Gansevoort R. T., Sparks C. E., Dullaart R. P. F., Inflammation reduces HDL protection against primary cardiac risk. European Journal of Clinical Investigation 2010 40 6 483 489 2-s2.0-77952633500 10.1111/j.1365-2362.2010.02287.x
132. Lassègue B., Griendling K. K., NADPH oxidases: functions and pathologies in the vasculature. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 4 653 661 2-s2.0-77950896739 10.1161/ATVBAHA.108.181610
133. Ago T., Kuroda J., Kamouchi M., Sadoshima J., Kitazono T., Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system review and perspective. Circulation Journal 2011 75 8 1791 1800 2-s2.0-79960792993 10.1253/circj.CJ-11-0388
134. Brandes R. P., Weissmann N., Schröder K., NADPH oxidases in cardiovascular disease. Free Radical Biology and Medicine 2010 49 5 687 706 2-s2.0-77955096004 10.1016/j.freeradbiomed.2010.04.030
135. Elahi M. M., Kong Y. X., Matata B. M., Oxidative stress as a mediator of cardiovascular disease. Oxidative Medicine and Cellular Longevity 2009 2 5 259 269 2-s2.0-77953415757 10.4161/oxim.2.5.9441
136. Frey R. S., Ushio-Fukai M., Malik A. B., NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxidants and Redox Signaling 2009 11 4 791 810 2-s2.0-60749137151 10.1089/ars.2008.2220
137. Lakshmi S. V. V., Padmaja G., Kuppusamy P., Kutala V. K., Oxidative stress in cardiovascular disease. Indian Journal of Biochemistry and Biophysics 2009 46 6 421 440 2-s2.0-77954323861
138. Pennathur S., Heinecke J. W., Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxidants and Redox Signaling 2007 9 7 955 969 2-s2.0-34250325126 10.1089/ars.2007.1595 (Pubitemid 46919596)
139. Nicholls S. J., Hazen S. L., Myeloperoxidase and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1102 1111 2-s2.0-20144383475 10.1161/01.ATV.0000163262.83456.6d (Pubitemid 40776595)
140. Heinecke J. W., The role of myeloperoxidase in HDL oxidation and atherogenesis. Current Atherosclerosis Reports 2007 9 4 249 251 2-s2.0-36048963850 10.1007/s11883-007-0027-2 (Pubitemid 350081468)
141. Smith J. D., Dysfunctional HDL as a diagnostic and therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 2 151 155 2-s2.0-75149173936 10.1161/ATVBAHA.108.179226
142. Urundhati A., Huang Y., Lupica J. A., Smith J. D., DiDonato J. A., Hazen S. L., Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. Journal of Biological Chemistry 2009 284 45 30825 30835 2-s2.0-71449125360 10.1074/jbc.M109.047605